Condition (MeSH)
Asthenopia
ClinicalTrials.gov lists 65 trials for Asthenopia or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
65 of the 65 trials are tagged with Asthenopia itself; the rest are tagged with a narrower condition beneath it.
When did Asthenopia trials start? (19)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 12
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 7 |
| 2025 | 10 |
| 2024 | 12 |
| 2023 | 8 |
| 2022 | 4 |
| 2021 | 5 |
| 2020 | 1 |
| 2019 | 1 |
| 2018 | 1 |
| 2017 | 2 |
Showing 10 of 19 earlier years.
Forecast of the full-year count, planned starts included, not rows of this table: about 8 trials starting in 2026 and about 10 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.
Recruitment duration, a model prediction: 4 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Asthenopia trials in? (6)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 1/2 | 1 |
| Phase 3 | 4 |
| Phase 4 | 2 |
| Not applicable | 48 |
| Observational | 9 |
How many Asthenopia trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 6 |
| Recruiting | 3 |
| Active, not recruiting | 1 |
| Completed | 43 |
| Terminated | 3 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Asthenopia trials? (3)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Alcon Research | 1 |
| Bio Nature Health | 1 |
| Essilor International | 1 |
Which drugs are being tested for Asthenopia? (2)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Diquafosol | 1 |
| Lutein | 1 |
Interventions as named in the registry (13)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Acupuncture | 1 |
| Probiotics | 1 |
| Injection for SC administration (120mg/syringe) | 1 |
| Stulln Eyedrops | 1 |
| Meticel Ofteno® | 1 |
Showing 5 of 13 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which publications cover Asthenopia? (33)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Astaxanthin (AstaReal<sup>®</sup>) Improved Acute and Chronic Digital Eye Strain in Children: A Randomized Double-Blind Placebo-Controlled Trial. | Advances in therapy | 2025 | Yes |
| Reading through the eyes of a university student: A double-masked randomised placebo-controlled cross-over protocol investigating coloured spectacle lens efficacy in adults with visual stress. | PloS one | 2025 | Yes |
| Effects of yoga facial massage on computer vision syndrome and ocular motor function: A randomised controlled trial. | Complementary therapies in medicine | 2025 | Yes |
| The Visually Induced Motion Sickness Susceptibility Questionnaire (VIMSSQ): Estimating Individual Susceptibility to Motion Sickness-Like Symptoms When Using Visual Devices. | Human factors | 2023 | Yes |
| Visualisation ergonomics and robotic surgery. | Journal of robotic surgery | 2023 | Yes |
Showing 5 of 33 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials, prevalence, rare-disease identity, and sub-conditions in mesh.